{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T15:08:21Z","timestamp":1790262501903,"version":"4.1.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Hangzhou Grand Biologic Pharmaceutical INC"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"DOI":"10.1007\/s12325-026-03792-0","type":"journal-article","created":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T14:36:05Z","timestamp":1790260565000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of HZBio1 in Chinese Healthy Subjects: A Randomized Phase 1a Study"],"prefix":"10.1007","author":[{"given":"Hongzhong","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanqing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruijie","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,24]]},"reference":[{"issue":"7","key":"3792_CR1","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185x.70375","volume":"28","author":"M Sun","year":"2025","unstructured":"Sun M, Lyu Z, Wang C, Li Y, Zhao D, Ran X, et al. 2024 Update of Chinese guidelines for diagnosis and treatment of hyperuricemia and gout part I: recommendations for general patients. Int J Rheum Dis. 2025;28(7):e70375. https:\/\/doi.org\/10.1111\/1756-185x.70375.","journal-title":"Int J Rheum Dis"},{"issue":"2","key":"3792_CR2","doi-asserted-by":"publisher","first-page":"134","DOI":"10.2478\/jtim-2022-0031","volume":"10","author":"J Song","year":"2022","unstructured":"Song J, Jin C, Shan Z, Teng W, Li J. Prevalence and risk factors of hyperuricemia and gout: a cross-sectional survey from 31 provinces in mainland China. J Transl Intern Med. 2022;10(2):134\u201345. https:\/\/doi.org\/10.2478\/jtim-2022-0031.","journal-title":"J Transl Intern Med"},{"issue":"1","key":"3792_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-017-0890-9","volume":"15","author":"T Bardin","year":"2017","unstructured":"Bardin T, Richette P. Impact of comorbidities on gout and hyperuricaemia: an update on prevalence and treatment options. BMC Med. 2017;15(1):123. https:\/\/doi.org\/10.1186\/s12916-017-0890-9.","journal-title":"BMC Med"},{"issue":"1","key":"3792_CR4","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","volume":"76","author":"P Richette","year":"2017","unstructured":"Richette P, Doherty M, Pascual E, Barskova V, Becce F, Casta\u00f1eda-Sanabria J, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017;76(1):29\u201342. https:\/\/doi.org\/10.1136\/annrheumdis-2016-209707.","journal-title":"Ann Rheum Dis"},{"key":"3792_CR5","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1136\/annrheumdis-2018-eular.1033","volume":"77","author":"J Yu","year":"2018","unstructured":"Yu J. FRI0224 Management to reducing liver function impairment when initiating febuxostat for gout based on the prediction nomogram. Ann Rheum Dis. 2018;77:653\u20134. https:\/\/doi.org\/10.1136\/annrheumdis-2018-eular.1033.","journal-title":"Ann Rheum Dis"},{"key":"3792_CR6","doi-asserted-by":"publisher","DOI":"10.12659\/msm.944314","volume":"30","author":"HH Huang","year":"2024","unstructured":"Huang HH, Chen YY, Fang YW, Liou HH, Wang JT, Tsai MH. Comparative Cardiovascular Risks of Febuxostat and Allopurinol in Patients with Diabetes Mellitus and Chronic Kidney Disease. Med Sci Monit. 2024;30:e944314. https:\/\/doi.org\/10.12659\/msm.944314.","journal-title":"Med Sci Monit"},{"issue":"12","key":"3792_CR7","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1124\/dmd.117.077818","volume":"45","author":"H Wang","year":"2017","unstructured":"Wang H, Peng Y, Zhang T, Lan Q, Zhao H, Wang W, et al. Metabolic epoxidation is a critical step for the development of benzbromarone-induced hepatotoxicity. Drug Metab Dispos. 2017;45(12):1354\u201363. https:\/\/doi.org\/10.1124\/dmd.117.077818.","journal-title":"Drug Metab Dispos"},{"issue":"8","key":"3792_CR8","doi-asserted-by":"publisher","first-page":"643","DOI":"10.2165\/00002018-200831080-00002","volume":"31","author":"MH Lee","year":"2008","unstructured":"Lee MH, Graham GG, Williams KM, Day RO. A benefit-risk assessment of benzbromarone in the treatment of gout. Was its withdrawal from the market in the best interest of patients? Drug Saf. 2008;31(8):643\u201365. https:\/\/doi.org\/10.2165\/00002018-200831080-00002.","journal-title":"Drug Saf"},{"key":"3792_CR9","doi-asserted-by":"publisher","unstructured":"Chinese Society of Endocrinology, Chinese Medical Association. Guideline for the diagnosis and management of hyperuricemia and gout in China (2019). Chin J Endocrinol Metab. 2020;36(01):1\u201313. https:\/\/doi.org\/10.3760\/cma.j.issn.1000-6699.2020.01.001.","DOI":"10.3760\/cma.j.issn.1000-6699.2020.01.001"},{"issue":"3","key":"3792_CR10","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1002\/art.22403","volume":"56","author":"JS Sundy","year":"2007","unstructured":"Sundy JS, Ganson NJ, Kelly SJ, Scarlett EL, Rehrig CD, Huang W, et al. Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout. Arthritis Rheum. 2007;56(3):1021\u20138. https:\/\/doi.org\/10.1002\/art.22403.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"3792_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-018-1782-x","volume":"20","author":"BF Mandell","year":"2018","unstructured":"Mandell BF, Yeo AE, Lipsky PE. Tophus resolution in patients with chronic refractory gout who have persistent urate-lowering responses to pegloticase. Arthritis Res Ther. 2018;20(1):286. https:\/\/doi.org\/10.1186\/s13075-018-1782-x.","journal-title":"Arthritis Res Ther"},{"issue":"9","key":"3792_CR12","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1136\/annrheumdis-2012-201795","volume":"72","author":"MA Becker","year":"2013","unstructured":"Becker MA, Baraf HS, Yood RA, Dillon A, V\u00e1zquez-Mellado J, Ottery FD, et al. Long-term safety of pegloticase in chronic gout refractory to conventional treatment. Ann Rheum Dis. 2013;72(9):1469\u201374. https:\/\/doi.org\/10.1136\/annrheumdis-2012-201795.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"3792_CR13","doi-asserted-by":"publisher","first-page":"722","DOI":"10.2146\/ajhp130571","volume":"71","author":"WM Gentry","year":"2014","unstructured":"Gentry WM, Dotson MP, Williams BS, Hartley M, Stafford KR, Bottorff MB, et al. Investigation of pegloticase-associated adverse events from a nationwide reporting system database. Am J Health Syst Pharm. 2014;71(9):722\u20137. https:\/\/doi.org\/10.2146\/ajhp130571.","journal-title":"Am J Health Syst Pharm"},{"issue":"9","key":"3792_CR14","doi-asserted-by":"publisher","first-page":"4892","DOI":"10.1111\/dom.16532","volume":"27","author":"F Sun","year":"2025","unstructured":"Sun F, Zhang J, Yan Z, Yu Q, Wang P, He Y, et al. Efficacy and safety of PEGylated uricase in healthy adults and patients with hyperuricaemia: A phase I, randomized, double-blind, dose-escalation, placebo-controlled trial. Diabetes Obes Metab. 2025;27(9):4892\u2013902. https:\/\/doi.org\/10.1111\/dom.16532.","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"3792_CR15","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1038\/s41584-023-01006-3","volume":"19","author":"N Schlesinger","year":"2023","unstructured":"Schlesinger N, P\u00e9rez-Ruiz F, Liot\u00e9 F. Mechanisms and rationale for uricase use in patients with gout. Nat Rev Rheumatol. 2023;19(10):640\u20139. https:\/\/doi.org\/10.1038\/s41584-023-01006-3.","journal-title":"Nat Rev Rheumatol"},{"issue":"2","key":"3792_CR16","doi-asserted-by":"publisher","first-page":"83","DOI":"10.7150\/ijms.4.83","volume":"4","author":"L Cammalleri","year":"2007","unstructured":"Cammalleri L, Malaguarnera M. Rasburicase represents a new tool for hyperuricemia in tumor lysis syndrome and in gout. Int J Med Sci. 2007;4(2):83\u201393. https:\/\/doi.org\/10.7150\/ijms.4.83.","journal-title":"Int J Med Sci"},{"issue":"3","key":"3792_CR17","doi-asserted-by":"publisher","first-page":"S31","DOI":"10.1016\/j.semarthrit.2020.04.011","volume":"50","author":"N Schlesinger","year":"2020","unstructured":"Schlesinger N, Lipsky PE. Pegloticase treatment of chronic refractory gout: update on efficacy and safety. Semin Arthritis Rheum. 2020;50(3):S31\u20138. https:\/\/doi.org\/10.1016\/j.semarthrit.2020.04.011.","journal-title":"Semin Arthritis Rheum"},{"key":"3792_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.vascn.2020.106678","volume":"102","author":"L Hong","year":"2020","unstructured":"Hong L, Wang Z, Wei X, Shi J, Li C. Antibodies against polyethylene glycol in human blood: a literature review. J Pharmacol Toxicol Methods. 2020;102:106678. https:\/\/doi.org\/10.1016\/j.vascn.2020.106678.","journal-title":"J Pharmacol Toxicol Methods"},{"issue":"1","key":"3792_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00622-4","volume":"8","author":"CJ Chang","year":"2017","unstructured":"Chang CJ, Chen CH, Chen BM, Su YC, Chen YT, Hershfield MS, et al. A genome-wide association study identifies a novel susceptibility locus for the immunogenicity of polyethylene glycol. Nat Commun. 2017;8(1):522. https:\/\/doi.org\/10.1038\/s41467-017-00622-4.","journal-title":"Nat Commun"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03792-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03792-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03792-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T14:36:08Z","timestamp":1790260568000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03792-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,24]]},"references-count":19,"alternative-id":["3792"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03792-0","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,24]]},"assertion":[{"value":"10 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Yu Wang and Qian Wang are employees of Hangzhou Grand Biologic Pharmaceutical INC. Yang Yu is an employee of Grand Life Sciences Group Limited. Hongzhong Liu, Xin Zheng, Chuanqing Yang, Wei Tian, Ruijie Wan and Hongyun Wang have nothing to disclose.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The trial was registered with clinicaltrials.gov (identifier NCT04765995) on January 12, 2021 and approved by the Ethics Committee for Drug Clinical Trials of Peking Union Medical College Hospital (approval number KS2020478). The trial was carried out in accordance with the revised Declaration of Helsinki and the Guidelines for Good Clinical Practice Requirements. The subjects enrolled in the trial provided written informed consent before participating.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}